Combining traditional systemic and biologic therapies for psoriasis.
The year 2010 marks 8 years since etanercept obtained approval from the Food and Drug Administration for the treatment of psoriatic arthritis. There are 6 biologic therapies approved by the Food and Drug Administration for the treatment of psoriasis and/or psoriatic arthritis. These biologics are often used in patients who have received, are receiving, or will receive in the future the traditional systemic antipsoriatics. In this article, the currently available data on combining these therapies are reviewed.
Heffernan
Michael P
MP
Clinical Dermatology, St. Louis, MO 63117, USA. heffernan@centralderm.com <heffernan@centralderm.com>
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001688:Biological Products / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003879:Dermatologic Agents / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D010789:Phototherapy; D011565:Psoriasis / Q000628:therapy*
D000893:Anti-Inflammatory Agents; D001688:Biological Products; D003879:Dermatologic Agents; D007155:Immunologic Factors